Mutation studies in CD3⁺, CD19⁺ and CD34⁺ cell fractions in myeloproliferative disorders with homozygous JAK2^V617F in granulocytes

This publication has 6 references indexed in Scilit:

• The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
  Blood, 2005
• JAK2 in Myeloproliferative Disorders Is Not Just Another Kinase
  Cell Cycle, 2005
• A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders
  New England Journal of Medicine, 2005
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
  Nature, 2005
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
  The Lancet, 2005
• Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
  Blood, 2003